Cas:52496-08-9 Poly(propylene glycol) diacrylate manufacturer & supplier

Chemical Name:Poly(propylene glycol) diacrylate

CAS.NO:52496-08-9

Synonyms:Benzene, 1,1′-methylenebis[2-chloro-4-isothiocyanato-;1,1′-Methylenebis(2-chloro-4-isothiocyanatobenzene);MFCD09025708;MFCD00081912

Molecular Formula:C₁₅H₈Cl₂N₂S₂

Molecular Weight:351.273

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:515.9±50.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.657

PSA:

Exact Mass:349.950592

LogP:7.68

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Benzene, 1,1′-methylenebis[2-chloro-4-isothiocyanato- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00081912 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD09025708 Use and application,MFCD00081912 technical grade,usp/ep/jp grade.

Related News: For skin rash, the difference in response rates for anifrolumab versus placebo at week 52 were 13.5% SLE Disease Activity Index (SLEDAI), 15.5% British Isles Lupus Assessment Group index (BILAG) and 15.6% modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (mCLASI). For arthritis, differences in response rates were 8.2% SLEDAI, 11.8% BILAG and 12.6% joint response. (S)-1-((2R,4R,6R)-4-(tert-Butyl-diphenyl-silanyloxy)-6-{(2R,6R)-6-[2-(4-methoxy-benzyloxy)-ethyl]-4-methylene-tetrahydro-pyran-2-ylmethyl}-tetrahydro-pyran-2-yl)-2-triethylsilanyloxy-ethanol manufacturers Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. [2,4′-Bioxazole]-5-carboxylic acid, 2′,4,5′-trimethyl-, ethyl ester suppliers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. (((1R,2R)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)cyclopropyl)difluoromethyl)phosphonic acid vendor & factory.